

RECEIVED  
CENTRAL FAX CENTER

JUN 28 2005

Atty Docket No. 17726A-000420US

PTO FAX NO.: 703-872-9306

ATTENTION: Examiner Wilson, Michael C.

Group Art Unit 1632

**OFFICIAL COMMUNICATION**  
**FOR THE PERSONAL ATTENTION OF**  
**EXAMINER Wilson, Michael C.**

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following documents in re Application of LEE et al., Application No. 10/028,726, filed December 21, 2001 for PRODUCTS AND METHODS FOR CONTROLLING THE SUPPRESSION OF THE NEOPLASTIC PHENOTYPE are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Amendment

Number of pages being transmitted, including this page: 5

Dated: June 28, 2005

  
Stephanie J. Whitehurst

***PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300***

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834  
Telephone: 415-576-0200  
Fax: 415-576-0300  
0466

60325565 v1

RECEIVED  
CENTRAL FAX CENTER

002/005

JUN 28 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 17726A-000420US  
Client Ref. No.: 1988-209

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On June 28, 2005

TOWNSEND and TOWNSEND and CRYSTAL LLP

By: Stephanie J. Whitehurst

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

LEE et al.

Application No.: 10/028,726

Filed: December 21, 2001

For: PRODUCTS AND METHODS FOR  
CONTROLLING THE SUPPRESSION  
OF THE NEOPLASTIC PHENOTYPE

Customer No.: 20350

Confirmation No.

Examiner: Wilson, Michael C.

Technology Center/Art Unit: 1632

AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed February 13, 2004, please enter the following amendments and remarks:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 4 of this paper.